557770-91-9

Basic information

• Product Name: [5-[7-(3-Chloropropoxy)quinazolin-4-ylamino]pyrazol-3-yl]acetic acid
• Synonyms: 2-(3-(7-(3-CHLOROPROPOXY)-QUINAZOLIN-4-YLAMINO)-1H-PYRAZOL-5-YL)ACETIC ACID;1H-Pyrazole-3-acetic acid, 5-[[7-(3-chloropropoxy)-4-quinazolinyl]amino]-;2-(5-((7-(3-chloropropoxy)quinazolin-4-yl)amino)-1H-pyrazol-3-yl)acetic acid;[5-[7-(3-Chloropropoxy)quinazolin-4-ylamino]pyrazol-3-yl]acetic acid;EOS-61779
• CAS NO: 557770-91-9
• Molecular Formula: C₁₆H₁₆ClN₅O₃
• Molecular Weight: 361.78
• Product Categories: API intermediates
• Mol File: 557770-91-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [5-[7-(3-Chloropropoxy)quinazolin-4-ylamino]pyrazol-3-yl]acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [5-[7-(3-Chloropropoxy)quinazolin-4-ylamino]pyrazol-3-yl]acetic acid(557770-91-9)
• EPA Substance Registry System: [5-[7-(3-Chloropropoxy)quinazolin-4-ylamino]pyrazol-3-yl]acetic acid(557770-91-9)

Safety Data

• Hazardous Substances Data: 557770-91-9(Hazardous Substances Data)

Usage

General Description

[5-[7-(3-Chloropropoxy)quinazolin-4-ylamino]pyrazol-3-yl]acetic acid is a chemical compound with a complex structure. It contains a quinazoline ring with an amino group, a pyrazole ring, and a chloropropoxy side chain. The compound also includes an acetic acid group as part of its structure. This chemical may have potential pharmaceutical or biological applications due to the presence of the quinazoline and pyrazole moieties, which are common structural components in many biologically active compounds. The presence of a chloropropoxy group can also impart specific chemical and biological properties to the compound. However, further research and testing would be necessary to determine the specific uses and effects of this compound.

Upstream product

• 446-32-2 4-fluoroanthranilic acid 
• 557770-89-5 4-(3-phenylpropylamino)-7-(2-chloroethoxy)quinazoline 
• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 174891-10-2 (5-amino-2H-pyrazol-3-yl)acetic acid 
• 557770-90-8 4-chloro-7-(3-chloropropoxy)quinazoline 

Downstream Products

• 722544-46-9 2-(5-{[7-(3-chloropropoxy)quinazolin-4-yl]amino}-2H-pyrazol-3-yl)-N-(3-fluorophenyl)acetamide 
• 557770-88-4 2-(5-{[7-(3-chloropropoxy)quinazolin-4-yl]amino}-2H-pyrazol-3-yl)-N-(2,3-difluorophenyl)acetamide 
• 557770-93-1 N-(2,3-difluorophenyl)-2-{3-[(7-{3-[(2R)-2-(2-hydroxymethyl)pyrrolidin-1-yl]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide 
• 722544-51-6 N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide 
• 722544-37-8 di-tert-butyl {(2R)-1-[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl phosphate 
• 722544-50-5 di-tert-butyl 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl phosphate 
• 957881-03-7 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)proplyl]amino}ethyl dihydrogen phosphate 

Relevant articles and documents

As Aurora kinase inhibitors of the substituted quinazoline derivatives

The invention relates to a substituted quinazoline derivative as an aurora kinase inhibitor, which is shown as structural formula (I) or (Ia), tautomers, hydrates, solvates or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the tautomers, hydrates, solvates and pharmaceutically acceptable salts as drug active ingredients, and application of the compounds and the pharmaceutical compositions in preparation of medicines for protection, treatment, curing or alleviation of proliferative diseases of patients.

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase

The Aurora kinases have been the subject of considerable interest as targets for the development of new anticancer agents. While evidence suggests inhibition of Aurora B kinase gives rise to the more pronounced antiproliferative phenotype, the most clinically advanced agents reported to date typically inhibit both Aurora A and B. We have discovered a series of pyrazoloquinazolines, some of which show greater than 1000-fold selectivity for Aurora B over Aurora A kinase activity, in recombinant enzyme assays. These compounds have been designed for parenteral administration and achieve high levels of solubility by virtue of their ability to be delivered as readily activated phosphate derivatives. The prodrugs are comprehensively converted to the des-phosphate form in vivo, and the active species have advantageous pharmacokinetic properties and safety pharmacology profiles. The compounds display striking in vivo activity, and compound 5 (AZD1152) has been selected for clinical evaluation and is currently in phase 1 clinical trials.